Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

FOLFIRINOX – a new paradigm in the treatment of pancreatic cancer

(2014) Dionysios Papadatos-Pastos et al.   Expert Review of Anticancer Therapy

Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

(2013) Matthew H. G. Katz et al.   ANNALS OF SURGICAL ONCOLOGY

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

(2013) A H Ko et al.   BRITISH JOURNAL OF CANCER

Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study

(2013) R. P. Jones et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells

(2013) S. E. Pratt et al.   CLINICAL CANCER RESEARCH

Clinical implications of CES2 RNA expression in neuroblastoma

(2013) Keiichi Uchida et al.   JOURNAL OF PEDIATRIC SURGERY

Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy

(2012) Ching-Wei D. Tzeng et al.   ANNALS OF SURGICAL ONCOLOGY

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

(2012) Matthew H. G. Katz et al.   CANCER

The pharmacological landscape and therapeutic potential of serine hydrolases

(2012) Daniel A. Bachovchin et al.   NATURE REVIEWS DRUG DISCOVERY

Detection and Quantification of Carboxylesterase 2 Activity by Capillary Electrophoresis

(2011) Joana Lamego et al.   ANALYTICAL CHEMISTRY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11

(2010) M. Jason Hatfield et al.   BIOCHEMICAL PHARMACOLOGY

Activity-based Proteomics of Enzyme Superfamilies: Serine Hydrolases as a Case Study

(2010) Gabriel M. Simon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis

(2009) Daniel K. Nomura et al.   CELL

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

(2009) Michael P Kim et al.   Nature Protocols

RBBP9: A tumor-associated serine hydrolase activity required for pancreatic neoplasia

(2009) D. J. Shields et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of an Integrated Biospecimen Bank and Multidisciplinary Clinical Database For Pancreatic Cancer

(2008) Rosa F. Hwang et al.   ANNALS OF SURGICAL ONCOLOGY

Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma

(2008) Hiroki Yano et al.   CANCER SCIENCE